- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05515354
Smoking Cessation and Menstrual Cycle Phase (MC-NRT)
Coordinating Smoking Cessation Treatment With Menstrual Cycle Phase to Improve Quit Outcomes: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Evidence for the influence of the menstrual cycle (MC) phase on smoking cessation outcomes is contradictory and has been limited by small samples and a lack of clarity surrounding ideal quit date timing. Therefore, this large rigorously designed study aims to clarify whether targeting quit date to either the follicular or luteal phase of MC improves quit success. The primary hypothesis states that participants assigned a TQD in the follicular phase of their MC will be more likely to have quit successfully on day 7 of treatment than participants setting their own TQD (usual care). Quit rates at the end of treatment and 6 months post-TQD were identified as secondary objectives.
Participants will enroll in an online smoking cessation program providing nicotine replacement therapy (NRT) and behavioral support. Participants will receive a 6-week supply of NRT consisting of nicotine patch plus their choice of nicotine gum or lozenge, which the participants will be instructed to start on their target quit date (TQD). Eligible individuals will be randomized to a TQD: [1] during the mid-luteal phase of their MC (6-8 days pre-onset of menses), [2] during the mid-follicular phase of their MC (6-8 days post-onset of menses), or [3] within 30 days of enrollment with no regard to MC phase (usual care). Behavioural support will consist of a free downloadable app (My Change Plan) and brief videos delivered via e-mail. These videos will be produced by the CAMH Nicotine Dependence Service and will focus on health behavior change strategies such as building a quit plan, coping with cravings, and relapse prevention.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Laurie A Zawertailo, PhD
- Phone Number: 77422 4165358501
- Email: laurie.zawertailo@camh.ca
Study Contact Backup
- Name: Tina Kabir, BMSc
- Phone Number: 37285 4165358501
- Email: tina.kabir@camh.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M6J 1H4
- Recruiting
- Centre for Addiction and Mental Health, Nicotine Dependence Clinic
-
Contact:
- Laurie Zawertailo
- Phone Number: 77422 416-535-8501
- Email: laurie.zawertailo@camh.ca
-
Principal Investigator:
- Laurie Zawertailo, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must provide informed consent following the CAMH REDCap e-consent framework and procedures;
- Stated willingness to comply with all study procedures;
- Naturally cycling individuals with regular MCs (defined as length ranging 21 to 35 days over past 6 months);
- Daily smoker of ≥5 cigarettes per day (CPD) over past 6 months;
- Intention to quit smoking within the next 30 days and willing to make a quit attempt on their assigned TQD;
- Interested in using, and able to use, nicotine patches and gum or lozenge as a smoking cessation aid;
- Willing to provide a valid e-mail address to be used for study communications and to complete online questionnaires.
Exclusion Criteria:
- Current use of progesterone, estrogen, testosterone, or fertility treatment;
- Current use of nicotine replacement therapy or other smoking cessation medications (e.g., varenicline, bupropion);
- Use of hormonal contraceptives in the past 6 months (e.g., pill, patch, hormonal intrauterine device [IUD], ring);
- Pregnancy, or trying to become pregnant in the next 2-3 months;
- Known hypersensitivity or allergies to any of the components of the nicotine patch;
- Daily or almost daily use of cannabis in the past 6 months;
- Daily or almost daily use of tobacco or nicotine products other than cigarettes (e.g., smokeless tobacco, heat-not-burn products, e-cigarettes) in the past 6 months;
- Polycystic ovary syndrome diagnosis;
- Unstable psychiatric condition (including substance use disorder) which would compromise study compliance;
- Life threatening arrhythmias or severe/worsening angina pectoris;
- Myocardial infarction or cerebral vascular accident in the past 2 weeks; or
- Diagnosed with a terminal illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mid-Follicular Phase Target Quit Date
Participants will start their quit attempts during the mid-follicular phase of their MC (6-8 days post-onset of menses).
Each participant will be provided with a range of appropriate dates based on the information about their menstrual cycle, and they will select a target quit date from the range.
Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
|
Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
Other Names:
Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks.
Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches.
For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
Other Names:
|
Experimental: Mid-Luteal Phase Target Quit Date
Participants will start their quit attempts during the mid-luteal phase of their MC (6-8 days pre-onset of menses).
Each participant will be provided with a range of appropriate dates based on the information about their menstrual cycle, and they will select a target quit date from the range.
Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
|
Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
Other Names:
Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks.
Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches.
For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
Other Names:
|
Active Comparator: Randomly Selected Target Quit Date (Usual Care)
Participants will start their quit attempts within 30 days of their enrollment into the study.
They will select their target quit dates without regard for their MC.
Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
|
Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks.
Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches.
For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
7-day point prevalence of abstinence
Time Frame: 7 days post-target quit date
|
Proportion of the sample that has been abstinent from smoking for 7 days at the time of assessment (i.e., managed to quit smoking on their target quit date).
|
7 days post-target quit date
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
End-of-treatment 7-day point prevalence of abstinence
Time Frame: 6 weeks post-target quit date
|
Proportion of the sample that has been abstinent from smoking for at least 7 days at the time of assessment.
|
6 weeks post-target quit date
|
Follow-up 7-day point prevalence of abstinence
Time Frame: 6 months post-target quit date
|
Proportion of the sample that has been abstinent from smoking for at least 7 days at the time of assessment.
|
6 months post-target quit date
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Carpenter MJ, Saladin ME, Leinbach AS, Larowe SD, Upadhyaya HP. Menstrual phase effects on smoking cessation: a pilot feasibility study. J Womens Health (Larchmt). 2008 Mar;17(2):293-301. doi: 10.1089/jwh.2007.0415.
- Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O'Brien CP, Childress AR. Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Womens Health (Larchmt). 2008 Mar;17(2):287-92. doi: 10.1089/jwh.2007.0423.
- Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, Loh WY. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. Nicotine Tob Res. 2010 Jun;12(6):647-57. doi: 10.1093/ntr/ntq067. Epub 2010 May 3.
- Poirier AE, Ruan Y, Grevers X, Walter SD, Villeneuve PJ, Friedenreich CM, Brenner DR; ComPARe Study Team. Estimates of the current and future burden of cancer attributable to active and passive tobacco smoking in Canada. Prev Med. 2019 May;122:9-19. doi: 10.1016/j.ypmed.2019.03.015.
- Saladin ME, McClure EA, Baker NL, Carpenter MJ, Ramakrishnan V, Hartwell KJ, Gray KM. Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy. Nicotine Tob Res. 2015 Apr;17(4):398-406. doi: 10.1093/ntr/ntu262.
- Smith PH, Bessette AJ, Weinberger AH, Sheffer CE, McKee SA. Sex/gender differences in smoking cessation: A review. Prev Med. 2016 Nov;92:135-140. doi: 10.1016/j.ypmed.2016.07.013. Epub 2016 Jul 26.
- Statistics Canada. (2020). Smokers, by age group. Retrieved August 23, 2021, from https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009610&pickMembers%5B0%5D=1.1&pickMembers%5B1%5D=3.3&cubeTimeFrame.startYear=2018&cubeTimeFrame.endYear=2019&referencePeriods=20180101%2C20190101
- World Health Organization. (2020). Who report on cancer: Setting priorities, investing wisely and providing care for all. World Health Organization. Retrieved August 12, 2022, from https://www.who.int/publications-detail-redirect/9789240001299
- Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, Gray KM, Mazure CM, Wetherington CL, McKee SA. Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation. Nicotine Tob Res. 2015 Apr;17(4):407-21. doi: 10.1093/ntr/ntu249.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Substance-Related Disorders
- Disease
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 022-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Timing of nicotine replacement therapy start date
-
Asan Medical CenterUnknownSeptic Shock | Acute Kidney Injury | Severe SepsisKorea, Republic of
-
University of ParmaUnknownAcute Renal Failure | Hypophosphatemia | Dialysis Related Complication | HypomagnesemiaItaly
-
University of Kansas Medical CenterPatient-Centered Outcomes Research InstituteCompletedSmoking | Pulmonary Disease, Chronic Obstructive | Tobacco Use DisorderUnited States
-
NYU Langone HealthNational Cancer Institute (NCI)Recruiting
-
Fred Hutchinson Cancer CenterPalo Alto Veterans Institute for Research; Bedford Research Corporation, Inc.; Jefferson Center, Community Mental Health Clinic and other collaboratorsCompletedSmoking | Bipolar DisorderUnited States
-
Rutgers, The State University of New JerseyCompleted
-
University of VermontActive, not recruitingNicotine Addiction | Quitting Smoking | E-Cig UseUnited States
-
Mark Vander WegIowa City VA Health Care SystemUnknownNicotine Dependence | Smokeless TobaccoUnited States
-
University of VermontCompletedTobacco Use DisorderUnited States
-
University of MonastirCompletedSmoking | Recurrence | Acute Coronary SyndromeTunisia